ATE267213T1 - Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind - Google Patents

Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Info

Publication number
ATE267213T1
ATE267213T1 AT98948429T AT98948429T ATE267213T1 AT E267213 T1 ATE267213 T1 AT E267213T1 AT 98948429 T AT98948429 T AT 98948429T AT 98948429 T AT98948429 T AT 98948429T AT E267213 T1 ATE267213 T1 AT E267213T1
Authority
AT
Austria
Prior art keywords
cea
agonists
antagonists
peptides
antigen
Prior art date
Application number
AT98948429T
Other languages
English (en)
Inventor
Jeffrey Schlom
Elene Barzaga
Sam Zaremba
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE267213T1 publication Critical patent/ATE267213T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98948429T 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind ATE267213T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6158997P 1997-10-10 1997-10-10
PCT/US1998/019794 WO1999019478A1 (en) 1997-10-10 1998-09-22 Agonist and antagonist peptides of carcinoembryonic antigen (cea)

Publications (1)

Publication Number Publication Date
ATE267213T1 true ATE267213T1 (de) 2004-06-15

Family

ID=22036775

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04011673T ATE364048T1 (de) 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität
AT98948429T ATE267213T1 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04011673T ATE364048T1 (de) 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität

Country Status (11)

Country Link
EP (1) EP1017810B1 (de)
JP (1) JP4291508B2 (de)
AT (2) ATE364048T1 (de)
AU (1) AU745863B2 (de)
CA (1) CA2308127C (de)
CY (1) CY1107706T1 (de)
DE (2) DE69824023T2 (de)
DK (1) DK1447414T3 (de)
ES (2) ES2217585T3 (de)
PT (1) PT1447414E (de)
WO (1) WO1999019478A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010379A2 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Modified cea and uses thereof
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
ES2337429T3 (es) * 1999-10-11 2010-04-23 Institut Pasteur Vectores lentivirales para la preparacion de composiciones inmunoterapeuticas.
CA2388301C (en) * 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2003059379A2 (en) * 2002-01-17 2003-07-24 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
US20060239962A1 (en) * 2002-12-04 2006-10-26 Banchereau Jacques F Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors
JP4914990B2 (ja) * 2002-12-16 2012-04-11 グローブイミューン,インコーポレイテッド 動物を癌から守るための治療用組成物
US7457855B2 (en) 2004-04-30 2008-11-25 Aol Llc Network configuration management
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
NZ582823A (en) 2007-07-27 2012-04-27 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584266B1 (de) * 1991-05-06 2003-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Also Published As

Publication number Publication date
DE69837896D1 (de) 2007-07-19
JP2002500002A (ja) 2002-01-08
EP1017810A1 (de) 2000-07-12
CA2308127C (en) 2011-03-22
JP4291508B2 (ja) 2009-07-08
DK1447414T3 (da) 2007-09-10
AU9500498A (en) 1999-05-03
CY1107706T1 (el) 2013-04-18
WO1999019478A1 (en) 1999-04-22
DE69837896T2 (de) 2008-02-14
ES2217585T3 (es) 2004-11-01
DE69824023D1 (de) 2004-06-24
DE69824023T2 (de) 2005-05-12
ES2286530T3 (es) 2007-12-01
ATE364048T1 (de) 2007-06-15
EP1017810B1 (de) 2004-05-19
PT1447414E (pt) 2007-07-18
CA2308127A1 (en) 1999-04-22
AU745863B2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
ATE272070T1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
NO923953L (no) Peptider
MY109957A (en) Improved antibodies to plasmodium falciparum
EP0606317A4 (en) Saponin-antigen conjugates and the use thereof.
DE69316948D1 (de) Lösliche Liganden für CD40
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
EA199800946A1 (ru) Концентрированный препарат антител
GEP20074091B (en) Cripto blocking antibodies and uses thereof
ES2124533T3 (es) Anticuerpos monoclonales inmunoestimulantes.
TR199801722T2 (xx) Peptit imm�nojenler.
EP0552296A4 (en) Mouse monoclonal antibodies
EP0739350A4 (de) Fas-antigenbindender ligand
ZA85206B (en) Protein conjugates useful in the treatment of thrombotic disease
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
EP1447414A3 (de) Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
EP1555316A3 (de) Antigenbibliothek Immunisierung
IT8320377A0 (it) Nuovo antigene per la ricerca della ipersensibilita' cutanea brucellica, specialmente nell'uomo. e suo procedimento di preparazione.
ATE480250T1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion
ES2199047A1 (es) Metodo de diagnostico inmunologico de la dirofilariosis pulmonar humana
NZ333191A (en) Human dendritic cell receptor DEC-205

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties